Systems and methods for improving medical treatments
This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications.
1. A method of automatically monitoring patient compliance or non-compliance with a medical treatment involving a therapeutic agent, comprising:
a) providing a sample of bodily fluid retrieved from said patient to a cartridge;
b) providing via an external device a plurality of analyte protocols for processing the sample, wherein each of the protocols measures a different analyte;
c) selecting automatically, with aid of a processor in said external device, at least one analyte protocol from said plurality of analyte protocols, wherein the selecting is determined by information associated with the cartridge;
d) allowing the sample of bodily fluid to react with one or more assay reagents from the cartridge in accordance with the at least one analyte protocol;
e) detecting, from the sample of bodily fluid, wherein at least one detectable signal indicative of the concentrations of said analyte;
f) comparing information regarding said signal with a known profile for said analyte to establish said compliance or non-compliance;
g) notifying said patient or a medical practitioner of the result of said comparison, thereby monitoring said patient compliance or non-compliance with the medical treatment involving the therapeutic agent.
2. The method of claim 1 , wherein the cartridge is inserted into a reader assembly comprising a communication assembly, and wherein the comparing step of (f) is effected by transmitting via the communication assembly information regarding said signal to said external device, where comparison of said signal with a known profile associated with said analytes is performed.
3. The method of claim 2 wherein the plurality of protocols is stored on said external device.
4. The method of claim 2 , wherein the detectable signal is a luminescent signal.
5. The method of claim 2 , wherein the detectable signal is a chemiluminescent signal.
6. The method of claim 1 , wherein said notification is transmitted electronically.
7. The method of claim 1 , wherein said notification is transmitted wirelessly.
8. The method of claim 1 , wherein said notification is transmitted via a handheld device.
9. The method of claim 1 , the sample of bodily fluid is less than about 500 ul .
10. The method of claim 1 , wherein the reactant comprises an immunoassay reagent.
11. The method of claim 1 , wherein said notification indicates compliance of said patient with said medical treatment.
12. The method of claim 1 , wherein said notification indicates lack of compliance of said patient with said medical treatment.
13. The method of claim 1 , wherein said monitoring takes place throughout the medical treatment.
14. The method of claim 1 , wherein the analyte is a biomarker.
15. The method of claim 1 , wherein the analyte is a drug.
16. The method of claim 1 , wherein the profile is based on the patient's own previous pharmacodynamic, pharmacokinetic, or pharmacogenetic profiles.
17. The method of claim 1 , wherein the analyte is a prodrug.
18. The method of claim 1 , wherein the analyte is a drug metabolite.
19. The method of claim 1 , wherein the analyte is a metabolite.
20. The method of claim 2 wherein the protocol to be run on by said reader assembly is stored on said external device.
21. The method of claim 20 further comprising transmitting the protocol from the external device to the fluidic device.
22. The method of claim 1 wherein the known profile is stored on said external device.
23. The method of claim 1 wherein the protocol is associated with said patient and comprises a time and/or date to test said sample of bodily fluid.
24. The method of claim 1 further comprising indicating that multiple doses of the therapeutic agent have been taken when a metabolite concentration detected by the reader assembly is at an elevated level compared to a known profile.
25. The method of claim 1 further comprising indicating that insufficient doses of the therapeutic agent have been taken when a metabolite concentration detected by the reader assembly is at a decreased level compared to a known profile.
26. The method of claim 1 wherein the patient is notified automatically after the signal is compared with a known profile.